Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI – Get Rating) has been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $4.69.
A number of research firms have recently weighed in on SPPI. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Spectrum Pharmaceuticals in a report on Friday. StockNews.com raised Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. B. Riley cut their price target on Spectrum Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Monday, March 21st. Zacks Investment Research raised Spectrum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Tuesday, May 24th. Finally, JMP Securities reaffirmed a “buy” rating and set a $4.00 price target on shares of Spectrum Pharmaceuticals in a report on Wednesday, April 13th.
NASDAQ SPPI traded up $0.03 during trading hours on Friday, reaching $0.74. The company’s stock had a trading volume of 2,114,816 shares, compared to its average volume of 1,765,586. The company has a current ratio of 2.38, a quick ratio of 2.38 and a debt-to-equity ratio of 0.10. The business has a 50-day simple moving average of $0.98 and a 200 day simple moving average of $1.09. Spectrum Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $4.54. The stock has a market cap of $132.91 million, a PE ratio of -0.84 and a beta of 2.23.
Several hedge funds and other institutional investors have recently bought and sold shares of SPPI. Moors & Cabot Inc. acquired a new position in Spectrum Pharmaceuticals in the third quarter worth approximately $26,000. Mirabella Financial Services LLP acquired a new position in Spectrum Pharmaceuticals in the first quarter worth approximately $27,000. Janus Henderson Group PLC acquired a new position in Spectrum Pharmaceuticals in the third quarter worth approximately $34,000. WINTON GROUP Ltd acquired a new position in Spectrum Pharmaceuticals in the first quarter worth approximately $35,000. Finally, Acadian Asset Management LLC acquired a new position in Spectrum Pharmaceuticals in the fourth quarter worth approximately $36,000. Institutional investors and hedge funds own 58.51% of the company’s stock.
About Spectrum Pharmaceuticals (Get Rating)
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.